Peter is a successful serial health-tech entrepreneur having been the founder of CliniCom Inc, a leader in the electronic medical record industry eventually acquired by McKesson; a Co-Founder of St. Jude Medical and former sales and marketing executive at Medtronic, both global leaders in the medical device industry. Peter started OncoGenesis with a passion for expanding cervical cancer screening access and improving early detection of cervical disease.
Dr. Vichi has over 25 years of academic and industry-related experience in pharmacology, oncology, biomedical technologies, and materials sciences. He served as VP and Chief Scientific Officer for Matrx Pharmaceuticals, Inc.: Chief Development Technical Officer, and founding member of CerMed, the predecessor to OncoGenesis; Senior Scientist for R&D at Diffraction, LTD.; and Creative MicroSystems Corp, which specialize in microfabrication and nanostructuring for prototype microfluidic and optoelectronic devices. He is a former faculty member in the Department of Biomedical Technologies at the University of Vermont (UMV). Dr. Vichi earned a PhD in Cellular & Molecular Biology and completed postdoctoral fellowships in Molecular Physiology and Biophysics at UVM and Cancer Biology at the Institut de Génétique et de Biologie, Moléculaire et Cellulaire (IGBMC), Strasbourg, France.
Scott brings more than 40 years of medical device and diagnostics industry experience to OncoGenesis. He has served in various senior management positions within OncoGenesis and is a member of the Board of Directors. Scott’s in-depth knowledge includes positions at Johnson & Johnson, 3M Healthcare, and Medtronic. Scott served as CEO of Bentec Medical, leading to a successful exit to strategic buyers. Scott also served as CEO of start-up Dynatherm Medical bringing the Company from concept to market to successful acquisition by Care Fusion. As President of Oridion Medical, he built market presence and revenues, leading to a successful IPO in Europe. Scott holds a BS in Chemistry from the University of California – Davis and an MBA from the University of California – Irvine.
Eric brings more than 30 years of healthcare technology commercialization experience to OncoGenesis. He has served in various sales, marketing, and business development roles including senior management positions for innovative, growth-stage companies in the US, Canada, Europe, and other markets. These include organizations such as Eclipsys (Allscripts), Ampersand Medical, Emis Inc., CareFx, Welldoc, Tickit Health, and others, as well as in advisory roles with many others. His activities have led to success in multiple markets including US, Canada, UK, Australia, France, Germany, Italy, Japan, New Zealand, and others. In his role of SVP of Commercialization, Eric is responsible for Business & Partnership Development, Sales, and Marketing.
Dr. Barcelo is a retired primary care and obstetrics physician and founding member of the Santa Lucia Medical Group. He has served as the Chair of the Department of Family Practice Medicine, Treasurer of the Medical Executive Committee, and a joint conference member at Salinas Valley Memorial Hospital. Dr. Barcelo served as a member of th
Dr. Barcelo is a retired primary care and obstetrics physician and founding member of the Santa Lucia Medical Group. He has served as the Chair of the Department of Family Practice Medicine, Treasurer of the Medical Executive Committee, and a joint conference member at Salinas Valley Memorial Hospital. Dr. Barcelo served as a member of the PRIME-US Advisory Board at UCSF School of Medicine and as the Vice-Chair of the Board of Trustees at Natividad Medical Center.
Tom Umbel has been the President and CEO of Seno Medical since January 2016. Tom led the Business Development efforts at Hologic, the largest dedicated Women’s Health company in the U.S. Tom’s role in managing mergers and acquisitions helped grow Hologic from a small single-product company with $100 million in revenue to a large diversifi
Tom Umbel has been the President and CEO of Seno Medical since January 2016. Tom led the Business Development efforts at Hologic, the largest dedicated Women’s Health company in the U.S. Tom’s role in managing mergers and acquisitions helped grow Hologic from a small single-product company with $100 million in revenue to a large diversified company with more than $2.5 billion during his 15 years. Among his Hologic accomplishments, he led the acquisition of Cytyc ($6.6 billion) and GenProbe. Prior to Hologic, Tom was President of Direct Radiology Corp. (DRC). He led the development and commercialization of the digital x-ray detector technology, which he ultimately sold to Hologic in 1999. This core market-leading digital mammography system is their engine to significant growth. Tom continues to serve on many medical device and diagnostic company boards. Tom holds a BS degree in chemical engineering from Grove City College.
Adam Henry is currently the Senior Vice President of Corporate Development at point-of-care instrument manufacturer, Proof Diagnostics, bringing over 25 years of biotechnology industry experience to the company. Adam’s career functional responsibilities have ranged in scope from corporate strategy, business development (M&A) and marketing
Adam Henry is currently the Senior Vice President of Corporate Development at point-of-care instrument manufacturer, Proof Diagnostics, bringing over 25 years of biotechnology industry experience to the company. Adam’s career functional responsibilities have ranged in scope from corporate strategy, business development (M&A) and marketing, specifically within the molecular diagnostics arena over the past 13 years, to product development, R&D and operations as a product design engineer earlier in his career at Invitrogen (now part of Thermo Fisher Scientific) and Dura Pharmaceuticals (acquired by Elan Pharmaceuticals).
Prior to joining Proof Dx in May 2022, Adam served as Head of Strategy and Business Development at Roche-subsidiary GenMark Dx. Before that, he held senior management roles at Siemens Healthineers, Hologic and Gen-Probe (acquired by Hologic) in strategy, business development and upstream marketing. During his tenure, Gen-Probe launched several highly innovative products including the PANTHER® molecular diagnostic system and the APTIMA® HPV screening assay, and the company’s value doubled, creating nearly $2 billion in value for shareholders, culminating in a successful sale of the business to Hologic in 2012. In total, Adam has facilitated nearly $6 billion in molecular diagnostics transactions since 2009.
Mr. Henry holds an MBA from the UCLA Anderson School of Management and a BS degree in Mechanical Engineering from the University of Nevada.
Dr. Shroyer is a Board Certified Anatomic Clinical Pathologist with a subspecialty certification in Cytopathology. He is an experienced surgical pathologist and cytopathologist and has maintained continuous externally funded grant support since 1993. Ken has been engaged in developing novel approaches for antibody labeling using nanoparticles for both in vivo imaging and for immunohistochemical applications in collaboration with scientists in biomedical engineering for over six years. Over the past 30 years, his work has been reported in over 140 research manuscripts, many of which are focused on the field of cervical cancer research. In addition to his roles as Chair of the Department of Pathology, staff surgical pathologist and cytopathologist, Dr. Shroyer is the vice-Chair of The University Clinical Management Practice Plan, President of the Stony Brook Pathology UFPC, a member of the Executive Board of the Cancer Center, and Director of the Pathology Core Research Histology Laboratory at Stony Brook Medicine. Ken has a BA from Colorado College, a PhD from the University of Colorado, and an MD from the University of Colorado School of Medicine.
Dr. J Rao is an internationally renowned cytopathologist and established investigator in cancer molecular epidemiology and biomarker studies. Before being a pathologist, he was already an established molecular epidemiologist involved in multiple high-profile cancer prevention studies. He completed his anatomical/clinical pathology residency and cytopathology fellowship at UCLA and joined the UCLA Department of Pathology as faculty. Dr. J. Rao is a full professor and the director of Cytopathology, the director of gynecological pathology, and the medical director of cytotechnology school. He has dual appointments in pathology and epidemiology. He is particularly well known for urine cytology, especially in utilizing biomarkers as an adjunct for detecting bladder cancer. He has been invited as a speaker for over 100 meetings and occasions locally, nationally, and internationally for cancer chemoprevention, biomarkers, urine cytology, Fine Needle Aspiration cytology, and gynecological pathology. Dr. Rao has an active role in teaching and research, with continuous funding from NIH or other agencies for cancer biomarker and prevention studies in the last 20 years, with over 100 peer-reviewed research publications. He is also interested in developing new technologies for pathology, especially Cytopathology, including imaging analysis, nanotechnology, and telepathology.